Dynamic changes of PD-1 expression on CD4 + and CD8 + T cells in patients with HBeAg-positive chronic hepatitis B treated with telbivudine
10.3760/cma.j.issn.1674-2397.2016.06.002
- VernacularTitle:HBeAg阳性慢性乙型肝炎患者外周血效应T淋巴细胞表面程序性死亡受体-1表达的研究
- Author:
Zhiqin LI
;
Jiajia ZHANG
;
Chunling HU
;
Yu PING
;
Hua LI
;
Jingya YAN
;
Jun LYU
;
Qinglei ZENG
;
Zujiang YU
;
Yi ZHANG
- Keywords:
Hepatitis B,chronic;
Antiviral agents;
Telbivudine;
Effective T lymphocyte cells;
Programmed cell death-1
- From:Chinese Journal of Clinical Infectious Diseases
2016;9(6):486-490
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the expression of PD-1 on CD4 +and CD8 + T cells in patients with HBeAg-positive chronic hepatitis B(CHB)treated with telbivudine.Methods Fifty-six HBeAg-positive CHB patients admitted in the First Affiliated Hospital of Zhengzhou University during January 201 3 and June 201 4 were enrolled in this study.The expression of PD-1 on CD4 +and CD8 + T cells was detected with flow cytometry at baseline,24,48 and 72 wks after telbivudine treatment.The relationship of PD-1 expression with alanine aminotransferase (ALT)level,HBeAg seroconversion and HBV DNA loads was analyzed.t test and completely random variance analysis were used to analyze the data.Results The PD-1 expression on CD4 + and CD8 + T cells at baseline was higher in patients with low ALT levels compared to those with high ALT levels(t =1 2.20 and 9.69,both P <0.01 ),while higher levels of PD-1 expression was also observed in patients with high HBV DNA load (≥5 lgIU /mL)compared to those with low HBV DNA load (t =4.39 and 4.85,both P <0.01 ).PD-1 levels on CD4 + and CD8 + T cells presented a declining trend after telbivudine treatment(F =6.98 and 8.97,both P <0.01 ),PD-1 expression in patients with HBeAg seroconversion showed lower levels compared with baseline values (t =1 8.45 and 1 8.01 ,both P <0.01 ). Conclusion In HBeAg-positive CHB patients,the expression of PD-1 on CD4 + and CD8 + T lymphocytes shows a decreasing trend during the treatment with telbivudine,indicating that antiviral therapy may alleviate the immunosuppression in these patients.
